Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$2.16 USD
+0.05 (2.37%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $2.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for Caribou Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 34 | 14 | 10 | 12 | 6 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 34 | 14 | 10 | 12 | 6 |
Selling & Adminstrative & Depr. & Amort Expenses | 151 | 120 | 77 | 48 | 40 |
Income After Depreciation & Amortization | -116 | -106 | -67 | -36 | -34 |
Non-Operating Income | 14 | 7 | 0 | 0 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -102 | -99 | -67 | -36 | -31 |
Income Taxes | 0 | 0 | 0 | -2 | -8 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -102 | -99 | -67 | -34 | -23 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -102 | -99 | -67 | -34 | -23 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -117 | -106 | -66 | -35 | -34 |
Depreciation & Amortization (Cash Flow) | -1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -116 | -106 | -67 | -36 | -34 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 73.81 | 60.80 | 31.66 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.38 | -1.64 | -2.11 | NA | NA |
Diluted Net EPS (GAAP) | -1.38 | -1.64 | -2.11 | NA | NA |
Fiscal Year end for Caribou Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 3.46 | 2.43 | 3.56 | 23.66 | 3.76 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 3.46 | 2.43 | 3.56 | 23.66 | 3.76 |
SG&A, R&D, and Dept/Amort Expenses | 46.97 | 48.43 | 41.00 | 38.29 | 36.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | -43.51 | -46.00 | -37.44 | -14.63 | -32.86 |
Non-Operating Income | 5.80 | 4.77 | 3.13 | 4.63 | 3.35 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -37.70 | -41.23 | -34.31 | -10.00 | -29.52 |
Income Taxes | 0.00 | 0.00 | 0.19 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -37.70 | -41.23 | -34.51 | -10.00 | -29.52 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -37.70 | -41.23 | -34.51 | -10.00 | -29.52 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 90.34 | 89.30 | 88.43 | 83.78 | 61.42 |
Diluted EPS Before Non-Recurring Items | -0.42 | -0.46 | -0.39 | -0.12 | -0.48 |
Diluted Net EPS (GAAP) | -0.42 | -0.46 | -0.32 | -0.12 | -0.48 |